MGF (5 mg Vial) Dosage Protocol
Mechano Growth Factor (MGF) is a splice variant of IGF-1 (IGF-1Ec in humans) produced in response to mechanical stress and tissue damage. Research indicates a role in muscle satellite cell activation, bone regeneration, and neurogenesis. Distinct from the PEGylated version (PEG-MGF) — MGF has a short half-life and acts as a localized tissue repair signal.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once daily | Half-life: Short (minutes)
Standard Approach (3 mL = 1.67 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 1.67 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Week 1 (titration) | 100 mcg | 6 units | 0.060 mL | 50 doses |
| Week 2 | 150 mcg | 9 units | 0.090 mL | 33 doses |
| Week 3 | 200 mcg | 12 units | 0.12 mL | 25 doses |
| Week 4 | 250 mcg | 15 units | 0.15 mL | 20 doses |
| Weeks 5–8 (target) | 300 mcg | 18 units | 0.18 mL | 16 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 30 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 200 mcg per dose, once daily (7 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| MGF (5 mg) vials | 3 vials | 4 vials |
| Insulin syringes (U-100) | 56 | 84 |
| Bacteriostatic water (10 mL) | 1 × 10 mL | 2 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
MGF (Mechano Growth Factor / IGF-1Ec) is a splice variant of IGF-1 produced in response to mechanical stress. Distinct from PEG-MGF — the non-PEGylated form has a short half-life (minutes) and acts as a localized tissue-repair signal rather than a systemic growth factor.
Effects appear tissue-specific and transient. Preclinical data supports roles in muscle satellite cell activation, bone regeneration, and neurogenesis.
Dosing Protocol
Daily titration (subcutaneous):
- Week 1 (titration): 100 mcg/day.
- Week 2: 150 mcg/day.
- Week 3: 200 mcg/day.
- Week 4: 250 mcg/day.
- Weeks 5–8 (target): 300 mcg/day. Most-cited maintenance dose.
Cycle: 8–12 weeks daily; optional extension to 16 weeks.
Timing: Post-workout dosing anecdotally favored to amplify mechanical-stress signaling. PEG-MGF (different peptide) offers extended-duration alternative.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
MGF is generated through alternative splicing of the IGF-1 gene in response to mechanical loading or tissue injury. The resulting peptide contains a unique C-terminal E domain distinct from systemic IGF-1. Preclinical research demonstrates MGF activates satellite cells (muscle stem cells), promotes osteoblast proliferation, and supports neurogenesis. Effects appear localized and transient — a tissue-specific repair signal.
Potential Benefits & Side Effects
Potential Benefits
- Satellite cell activation and myoblast proliferation.
- Bone defect healing in animal models.
- Neurogenesis and neuroprotection in aging brain tissue.
Side Effect Profile
- Generally well-tolerated in preclinical settings.
- Occasional injection-site reactions.
- Long-term human safety data limited.
Lifestyle Factors
- Pair with resistance training — mechanical stimulus naturally upregulates MGF expression.
- Adequate protein intake (1.6–2.2 g/kg).
- Prioritize sleep for growth factor activity.
Injection Technique
- Subcutaneous, rotate sites.
- Time near workout for localized effect.